Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2006

View Archived Issues

Preclinical update on the vascular benefits of NCX-6550

Potential of EGFR-related protein in colorectal cancer treatment examined in vivo

Ezetimibe/simvastatin superior to rosuvastatin in primary hypercholesterolemia

Recent results with bevacizumab in gastrointestinal cancers

ACZ-885 induces remission in Muckle Wells syndrome

TRU-015 pharmacodynamics assess in rheumatoid arthritis patients

Preclinical analysis of the antidepressive effects of galanin-3 receptor antagonism

Avastin studied in Australian trial for age-related macular degeneration

Innovate Oncology changes name to Avantogen Oncology

EQiTX restructures synthetic vaccine project

Norwood completes pilot BMT study in Australia

ABIO 08-01 begins Austrian phase II study in generalized anxiety disorder

OctoPlus acquires full rights to OP-145

FDA clears protocol amendment for phase I/II trials of HMPL-002

Sanofi-aventis licenses oral anticancer agent S-1 from Taiho

Biofusion invests in Adjuvantix

MK-677 slows sarcopenia in healthy elderly subjects

EP-01572 pharmacokinetics, pharmacodynamics evaluated in healthy men

Nicosan approved in Nigeria

A prodrug of 3-n-butylphtalide (NBP) may be useful for the treatment of cerebral ischemia

DiaPep277 mechanism of action involves TLR2-dependent modulation of regulatory T cell function

New lembehyne analogue shows antitumor activity in human neuroblastoma cell line

Recent patents disclose novel agents for gastrointestinal disorders

Dual NOS/COX-2 inhibitors claimed in Asineks patent

Recent patents describe novel treatment options for diabetes and associated disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...